Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural phenomenon.

Carlsmed (Nasdaq:CARL) today announced new technology add-on payment (NTAP) reimbursement for its spine implant technology.

As policymakers in the U.S. and globally consider how to govern artificial intelligence technology, Berkeley researchers have ...

Dr. Marten den Haring, an A.I. entrepreneur and CEO of Lirio, explores the U.S. government’s early efforts to modernize ...

Medicare Advantage (MA) payer Alignment Healthcare is raising its full-year guidance across the board after its first-ever ...

Artificial Intelligence (AI) continues to revolutionize industries and is poised to bring transformative change in healthcare delivery, ...

Of the nearly 700 such devices captured in STAT’s Breakthrough Device Tracker, at least 10% use artificial intelligence. At least 16 have already been authorized by the FDA, and the unofficial count ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A ...

Centene Corporation (NYSE:CNC) is one of the stocks that look extremely cheap on paper. On July 15, 2025, Oppenheimer ...

Effective board governance in complex health systems requires structured approaches that cascade quality and safety ...

Those who are willing to build relationships, leverage modern tools and commit to the long game can establish a thriving ...